Platform|API|Archive|Contact

Humanexa SignalsPharmaceutical Intelligence

FDA
EMA
MHRA
PMDA
Health Canada

Phase I
Phase II
Phase III
Readouts
Enrollment Signals

Pipeline Tracking
Company Moves
Asset Intelligence
Landscape Reports

Pricing
Access
Commercial
Launch Tracking

Licensing
Acquisitions
Partnerships
Capital Raises

Strategy Catalysts Pricing

Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

Regulatory
Clinical
Competitive
Markets
M&A Watch
Strategy
Catalyst Tracker

Company

Pricing
Partner with us
Subscribe
Contact
Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Asset / Drug

Bristol-Myers

Drug and asset intelligence for Bristol-Myers with 5 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 5
Catalysts: 0
Stage: Development stage unavailable

Sponsor company

Bristol Myers Squibb →

Mechanism of action

Immunomodulator

Recent signals(5)

ClinicalAugust 14, 2026

Bristol-Myers Squibb initiates KarXT trial for adolescent schizophrenia

Bristol-Myers Squibb is conducting a study to evaluate the efficacy and safety of KarXT for treating schizophrenia in adolescents.

RegulatoryJuly 31, 2026

FDA Acceptance of Supplemental Application for Thalidomide by Bristol-Myers

The FDA has accepted a supplemental application for Thalidomide (NDA020785) submitted by Bristol-Myers.

Clinical

July 14, 2026

Bristol-Myers Squibb initiates Phase 3 trial for KarXT + KarX-EC in Alzheimer's agitation

A Phase 3 study has been launched to assess the safety and efficacy of KarXT + KarX-EC for treating agitation in Alzheimer's patients.

RegulatoryJuly 6, 2026

FDA Approves Supplemental Application for Thalidomide (Thalomid)

The FDA has approved a supplemental application for Thalomid (thalidomide) submitted by Bristol-Myers.

ClinicalJune 29, 2026

Bristol-Myers Squibb Evaluates KarXT for Bipolar-I Disorder Manic Episodes

A clinical trial is underway to assess the efficacy and safety of KarXT in treating manic episodes of Bipolar-I Disorder.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts

No catalysts indexed for this entity yet.

Indications

Alzheimer's Disease →

Bipolar Disorder →

Therapeutic areas

Alzheimer's Disease →

Bipolar Disorder →

Immunomodulator →

Multiple Myeloma →

Schizophrenia →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.